Displaying drugs 801 - 825 of 1526 in total
CYC-065
CYC-065 is under investigation in clinical trial NCT03739554 (CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory CLL).
Investigational
AVI-014
AVI-014 is a glycosylated, recombinant human granulocyte colony-stimulating factor (G-CSF).
Investigational
DCP-001
Investigational
MT-0169
MT-0169 is a usion protein comprised of an enzymatically active Shiga-like toxin-I A1 subunit fused to a human single chain variable fragment with affinity for human CD38 cell surface protein.
Investigational
SIG-007
SIG-007 is a gene therapy that consists of cells that are genetically modified with a non-viral vector to express human alpha-galactosidase A. Developed by Sigilon Therapeutics, t is being investigated for the treatment of Fabry Disease.
Investigational
BTZ-043
Investigational
ICG-001
Investigational
TSN-084
Investigational
TCB-008
TCB-008 is an Allogeneic CD3+ T lymphocyte ex vivo expanded expressing the gamma delta T-cell receptor.
Investigational
GL-0719
Investigational
NVD-001
Investigational
CER-001
CER-001 is a negatively charged lipoprotein particle comprising human recombinant apolipoprotein A-I and two phospholipids: sphingomyelin and dipalmitoylphosphatidylglycerol. It is under investigation for the treatment of lecithin-cholesterol acyltransferase (LCAT) deficiencies.
Investigational
Phthalocyanine
Phthalocyanine is under investigation in clinical trial NCT00103246 (Photodynamic Therapy Using Silicon Phthalocyanine 4 in Treating Patients With Actinic Keratosis, Bowen's Disease, Skin Cancer, or Stage I or Stage II Mycosis Fungoides).
Investigational
Matched Iupac: … 2,11,20,29,37,38,39,40-octaazanonacyclo[28.6.1.1³,¹⁰.1¹²,¹⁹.1²¹,²⁸.0⁴,⁹.0¹³,¹⁸.0²²,²⁷.0³¹,³⁶]tetraconta …
Somatropin pegol
Somatropin pegol is under investigation in clinical trial NCT00715689 (Dose Study in Growth Hormone Deficient Adults Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC126-0083).
Investigational
Leronlimab
Leronlimab, or PRO-140, is a human monoclonal antibody developed by CytoDyn. It was first described in the literature in 2001. This antibody binds to CCR5, which may be useful in treating HIV, cancers, and severely ill COVID-19 patients.[A192846,A192858,L12684]
Investigational
MB-07803
MB07803 is a second generation gluconeogenesis inhibitor for the treatment of type 2 diabetes. It is designed to block the metabolic pathway in the liver that is responsible for producing glucose.
Investigational
MBT-0312
MediGene's newly acquired drug candidates MBT-0312 aim at a novel method of cancer therapy by "starving out" tumors.
Investigational
AZD-0424
AZD0424 has been used in trials studying the treatment of Advanced Solid Tumours.
Investigational
GDC-0927
GDC-0927 is under investigation in clinical trial NCT02316509 (A Study of GDC-0927 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer).
Investigational
VM4-037
VM4-037 is under investigation in clinical trial NCT00884520 (An Exploratory, Open Label, Multi-Center, Non-Randomized Study of [F-18]VM4-037).
Investigational
SOBI-003
SOBI-003 is a chemically modified variant of a recombinant human sulfamidase. It is under investigation in clinical trial NCT03811028 (A Study to Assess the Safety, Tolerability, and Efficacy of Long-term SOBI003 Treatment in Pediatric MPS IIIA Patients).
Investigational
YS-ON-001
YS-ON-001 is a combination of an inactivated purified rabies virus (IPRV) and the PIKA adjuvant (Poly I:C, kanamycin and calcium).
Investigational
TASO-001
TASO-001 is a transforming growth factor (TGF)-beta 2 specific antisense oligodeoxynucleotide.
Investigational
ETBX-051
Investigational
Displaying drugs 801 - 825 of 1526 in total